EdgarLookup

CXApp Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that CXApp Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-294%
Profit Margin
Net income ÷ revenue
-41.5%
Return on Assets
Net income ÷ assets
1.32x
Debt-to-Equity
Total liabilities ÷ equity
-35.8%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $4.58M Mar 30, 2026
FY2025 Dec 31, 2024 $7.14M Mar 30, 2026

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $888.0K Mar 30, 2026
FY2025 Sep 30, 2025 $991.0K Mar 30, 2026
FY2025 Jun 30, 2025 $1.05M Mar 30, 2026
FY2025 Mar 31, 2025 $1.07M Mar 30, 2026
FY2025 Dec 31, 2024 $1.43M Mar 30, 2026
FY2025 Sep 30, 2024 $1.53M Mar 30, 2026
FY2025 Jun 30, 2024 $1.41M Mar 30, 2026
FY2025 Mar 31, 2024 $1.49M Mar 30, 2026
FY2024 Dec 31, 2023 $5.62M Apr 7, 2025

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($13.47M) Mar 30, 2026
FY2025 Dec 31, 2024 ($19.41M) Mar 30, 2026
FY2022 Dec 31, 2022 $8.35M Apr 21, 2023
FY2022 Sep 30, 2022 $9.52M Apr 21, 2023
FY2022 Jun 30, 2022 $783.4K Apr 21, 2023
FY2022 Dec 31, 2021 $9.21M Apr 21, 2023
FY2021 Dec 31, 2020 ($4.08M) Mar 30, 2022

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($17.58M) Mar 30, 2026
FY2025 Dec 31, 2024 ($13.74M) Mar 30, 2026
FY2022 Dec 31, 2022 ($2.95M) Apr 21, 2023
FY2022 Dec 31, 2021 ($1.50M) Apr 21, 2023
FY2021 Dec 31, 2020 ($252.8K) Mar 30, 2022

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $6.64M Mar 30, 2026
FY2025 Dec 31, 2024 $6.38M Mar 30, 2026

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($10.38M) Mar 30, 2026
FY2025 Dec 31, 2024 ($7.33M) Mar 30, 2026
FY2022 Dec 31, 2022 ($761.1K) Apr 21, 2023
FY2022 Dec 31, 2021 ($595.3K) Apr 21, 2023
FY2021 Dec 31, 2020 ($514.7K) Mar 30, 2022

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $23.0K Mar 30, 2026
FY2025 Dec 31, 2024 $30.0K Mar 30, 2026

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $32.43M Mar 30, 2026
FY2025 Dec 31, 2024 $31.80M Mar 30, 2026
FY2023 Dec 31, 2023 $36.58M May 24, 2024
FY2023 Dec 31, 2022 $33.43M May 24, 2024
FY2022 Dec 31, 2021 $279.37M Apr 21, 2023
FY2021 Dec 31, 2020 $280.24M Mar 30, 2022

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $18.45M Mar 30, 2026
FY2025 Dec 31, 2024 $16.21M Mar 30, 2026
FY2023 Dec 31, 2023 $11.18M May 24, 2024
FY2023 Dec 31, 2022 $9.84M May 24, 2024
FY2022 Dec 31, 2021 $21.70M Apr 21, 2023
FY2021 Dec 31, 2020 $31.79M Mar 30, 2022

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $13.98M Mar 30, 2026
FY2025 Dec 31, 2024 $15.59M Mar 30, 2026
FY2025 Dec 31, 2023 $25.40M Mar 30, 2026
FY2023 Dec 31, 2022 $23.59M May 24, 2024
FY2022 Dec 31, 2021 ($21.09M) Apr 21, 2023
FY2022 Dec 31, 2020 ($30.30M) Apr 21, 2023
FY2021 Jul 19, 2020 $0 Mar 30, 2022

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $6.59M Mar 30, 2026
FY2025 Dec 31, 2024 $8.74M Mar 30, 2026

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($90.68M) Mar 30, 2026
FY2025 Dec 31, 2024 ($77.21M) Mar 30, 2026
FY2022 Dec 31, 2022 ($3.72M) Apr 21, 2023
FY2022 Dec 31, 2021 ($21.09M) Apr 21, 2023
FY2021 Dec 31, 2020 ($30.30M) Mar 30, 2022

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $11.10M Mar 30, 2026
FY2025 Dec 31, 2024 $4.88M Mar 30, 2026
FY2022 Dec 31, 2022 $224.5K Apr 21, 2023
FY2021 Dec 31, 2021 $406.1K Mar 30, 2022